L'intérêt à découvert pour Baxter Intl donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Baxter Intl. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Baxter Intl (NYSE:BAX) Stock, Rapport sur les intérêts à découvert

Baxter Intl

Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. It has signed an agreement to sell its kidney care segment by early 2025.

Baxter International

Baxter International Inc

BABB

BAXTER INTERNATIONAL ORD

Stryker Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/syk#NYSE">SYK</a>) has witnessed substantial gains in the year-to-date period. Shares of the company have rallied 18.6% compared with 13.4% growth of the&nbsp;industry. The S&amp;P 500 Composite has risen 20.1% during the same time frame.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for investors at the moment.
Headquartered in Kalamazoo, MI, Stryker is one of the world&#39;s largest medical device companies operating in the global orthopedic market. The company has three business segments &mdash; Orthopaedics, MedSurg and Neurotechnology &amp; Spine.
Strength in Stryker&#39;s flagship Mako Total Knee Platform, which enables surgeons to do pre-operative planning and precise surgeries, looks promising. The company is also adopting several cost-cutting measures, including restructuring plans. Its prospects seem promising on the back of strong customer demand for its existing products as well as new launches. Stryker&#39;s recent acquisitions also raise optimism about the stock.&nbsp;
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/01/80132.jpg?v=2080810141" />
Image Source: Zacks Investment Research
<h2>Catalysts for Stryker&#39;s Growth</h2>
The surge in the company&#39;s share price can be attributed to its advanced robotic arm-assisted surgery platform, Mako, a strong product lineup and strategic acquisitions. The positive sentiment, driven by a solid second-quarter fiscal 2024 performance and promising business potential, is expected to continue aiding it.
Stryker ended the second quarter on a high note, with both earnings and revenues showing year-over-year improvement. The company saw robust performance in the U.S. market, particularly in Instruments, Medical, Endoscopy, Trauma and Extremities, and Mako, which likely boosted the stock&#39;s price.
SYK has increased its revenue and earnings forecasts for fiscal 2024, likely attracting investor interest. The company now anticipates organic revenue growth of 9-10% for fiscal 2024, up from the previous guidance of 8.5-9.5%. Adjusted earnings per share for 2024 are now expected to be between $11.90 and $12.10, indicating 12% growth at the midpoint compared with the earlier projection of $11.85-$12.05.
SYK&#39;s extensive product range has also garnered investor optimism. Its broad product spectrum shields it from significant sales declines during economic downturns. The company&#39;s vast experience in medical robotics, artificial intelligence and mechatronics has kept it at the forefront of the MedTech industry.
In August, SYK launched the Pangea Plating System, which received FDA clearance in late 2023. The Pangea System offers variable-angle plating for diverse patient demographics with a comprehensive and adaptable portfolio. With the Pangea System, Stryker has become a key partner for trauma-related products, including plates, nails and external fixation devices, supported by dedicated staff and excellent service.
In June, Stryker introduced the LIFEPAK 35 monitor/defibrillator, a device featuring advanced technology aimed at improving workflow efficiency and providing advanced clinical solutions for emergency responders and healthcare professionals. Additionally, the company launched the Gamma4 Hip Fracture Nailing System in Germany on June 4.
In addition to expanding organically, Stryker has bolstered its expansion by way of acquisitions. Last month, the company completed the buyout of Vertos Medical, a privately held company providing a minimally invasive solution for treating chronic lower back pain caused by lumbar spinal stenosis.As a result of the acquisition, Stryker is set to expand its minimally invasive pain management portfolio with differentiated treatments and expand its reach across ambulatory surgery centers.
In June, Stryker also acquired care.ai, a privately held company specializing in AI-assisted virtual care workflows, smart room technology and ambient intelligence solutions. The company closed the acquisition of NICO Corporation, a privately held company providing a systematic approach to minimally invasive surgery for tumor and intracerebral hemorrhage procedures, in September.
SYK also announced the completion of the acquisition of MOLLI Surgical Inc., a privately held company specializing in the development of wire-free soft tissue localization technology for breast-conserving surgery, in August. In July, Stryker completed the previously announced acquisition of Artelon, a privately held company specializing in innovative soft tissue fixation products for foot and ankle and sports medicine procedures.
<h2>Risk Factors</h2>
As Stryker continues to acquire a large number of companies, which improves revenue opportunities, it is also likely to add to integration risks, putting gross and operating margins under pressure. Frequent acquisitions may affect the company&#39;s balance sheet in the form of a high level of goodwill and intangible assets.
A negative change in exchange rates is also a threat to SYK&#39;s core operations. The trend is likely to continue for the rest of 2024, though, at a slower pace. The company is also facing inflationary pressure, leading to lower margins.
<h2>A Look at Estimates</h2>
SYK&#39;s EPS for fiscal 2024 and 2025 is projected to increase 13.2% and 12.1% to $12.00 and $13.45 on a year-over-year basis, respectively.&nbsp; The Zacks Consensus Estimate for EPS for fiscal 2024 and 2025 has remained stable over the past 30 days.
Revenues for fiscal 2024 and 2025 are anticipated to rise 9.2% and 7.8%, respectively, to $22.37 billion and $24.12 billion on a year-over-year basis.
<div class="chart_embed">
<h3>Stryker Corporation Price</h3>
<img alt="Stryker Corporation Price" src="https://staticx-tuner.zacks.com/images/charts/bc/1727950805.png" style="height:254px; width:527px" title="" />
Stryker Corporation price | Stryker Corporation Quote
</div>
<h2>Stocks to Consider</h2>
Some better-ranked stocks in the broader medical space are&nbsp;Universal Health Service&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uhs#NYSE">UHS</a>),&nbsp;Quest Diagnostics&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>) and&nbsp;Baxter International&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bax#NYSE">BAX</a>), each carrying a Zacks Rank #2 (Buy).
Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Service has gained 47% compared with the&nbsp;industry&#39;s&nbsp;47.7% rise so far this year.
Quest Diagnostics has an estimated long-term growth rate of 6.2%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have gained 12.3% so far this year compared with the&nbsp;industry&#39;s&nbsp;19% rise.
Baxter&#39;s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 3.74%.
BAX&#39;s shares have declined 6.9% so far this year against the&nbsp;industry&#39;s&nbsp;13.3% growth.
<a href="https://www.zacks.com/stock/news/2345185/stryker-stock-gains-18-6-ytd-what-s-driving-its-share-price?cid=CS-BENZ-FT-analyst_blog|price_surge_/_plunge-2345185">To read this article on Zacks.com click here.</a>

Earnings

Earnings Beats

Large Cap

News

Guidance

Health Care

Markets

Analyst Ratings

Tech

Trading Ideas

General

Stryker Stock Gains 18.6% YTD: What's Driving its Share Price?

During the last three months, 6 analysts shared their evaluations of Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $38.17, a high estimate of $42.00, and a low estimate of $30.00. This current average represents a 4.17% decrease from the previous average price target of $39.83. 
<img src="https://www.benzinga.com/files/images/story/2024/1727802094_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Baxter Intl among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$42.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$30.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Baxter Intl. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Baxter Intl compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Baxter Intl's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Baxter Intl's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BAX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Baxter Intl analyst ratings.</a>
<h2>Delving into Baxter Intl's Background</h2>
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. It has signed an agreement to sell its kidney care segment by early 2025.
<h3>Understanding the Numbers: Baxter Intl's Finances</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Baxter Intl showcased positive performance, achieving a revenue growth rate of 2.83% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -8.24%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Baxter Intl's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -3.97%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Baxter Intl's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.16%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Baxter Intl's debt-to-equity ratio surpasses industry norms, standing at 1.75. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 6 Analysts Discuss Baxter Intl Stock

Citigroup analyst Joanne Wuensch maintains Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) with a Neutral and raises the price target from $38 to $40.

Price Target

Citigroup Maintains Neutral on Baxter Intl, Raises Price Target to $40

Baxter International Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>). has shut down its largest manufacturing facility following significant damage caused by Hurricane Helene. The hurricane, which hit the Southeast of the U.S. with deadly force, triggered power outages and flooding across the region.
Baxter's North Cove plant, located in Marion, North Carolina, is the nation's biggest producer of intravenous and peritoneal dialysis solutions. The company has stated that this disruption will likely have a negative effect on its financial performance.
On Monday, Baxter's shares initially fell as much as 4.1%, but later settled at a 2.3% decline, trading at $38.01 by midday in New York. Baxter&#8217;s stock ended up closing right below $38 a share Monday. Read Also: <a href="https://www.benzinga.com/news/24/09/41082452/hurricane-helene-exposes-vulnerability-of-floridas-home-insurance-market">Hurricane Helene Exposes Vulnerability Of Florida&#8217;s Home Insurance Market</a> Patrick Wood, an equity analyst at Morgan Stanley, covered the hurricane-related disruption in a note Monday, outlining the potential financial harm caused by the storm. Wood pointed to a 2017 hurricane, which impacted Baxter&#8217;s capacity in Puerto Rico, as a precedent for Hurricane Helene. &#8220;To sense check, if we assumed a $140mn impact in BAX's Q4 (given Q3 is essentially over), that implies about 4 days worth of shutdown for the entire US Chronic Therapies and Infusion Therapies businesses,&#8221; Wood wrote in the note. &#8220;Though in reality more given this is unlikely the only facility where PD and IV solutions are produced and BAX can presumably shift capacity around.&#8221;
Hurricane Helene, a Category 4 storm, struck Florida on Thursday with winds reaching 140 miles per hour and moved northward. The storm caused severe flooding, including a levee breach that sent water into Baxter&#8217;s facility. The flooding damaged stock and raw materials, according to a company spokesperson.
It remains unclear if the plant closure will affect medical procedures in the U.S., though Wells Fargo analysts noted that other companies, such as ICU Medical, Fresenius Kabi and B Braun SE, may be able to compensate for Baxter's supply loss.
Baxter is working closely with local officials to bring the North Cove plant back online. Fortunately, none of the facility's 2,500 employees were injured. However, the company is still verifying the safety of its workforce as communication in the area has been hampered by outages in cellular service. Keep Reading: • <a href="https://www.benzinga.com/24/09/41082266/hurricane-helene-devastates-southeastern-u-s-slamming-infrastructure-and-leaving-millions-powerless">Hurricane Helene Devastates Southeastern U.S., Slamming Infrastructure And Leaving Millions Powerless</a>

Photo: Unsplash

Analyst Color

Hurricane Helene Shutters Baxter International's Key Manufacturing Hub In North Carolina

The Vest APX System supports daily therapy for adults and children with certain chronic lung conditions and retained secretions. The system features the same trusted airflow technology as the previous version, with enhanced comfort and additional patient-centered features driven by clinician and patient input.&nbsp;

Baxter Unveiled Its Next Generation Airway Clearance System, The Vest Advanced Pulmonary Experience System, At The North American Cystic Fibrosis Conference

Thursday, Medtronic Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) said it is recalling certain devices and updating use instructions for another due to the possibility that the battery may deplete below its <a target="_blank" href="https://www.benzinga.com/quote/MDT" rel="noreferrer noopener">designed threshold</a>.
If this happens, it increases the risk of battery instability and may lead to increased battery temperature and a potential explosion.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40462317/medical-devices-giant-medtronic-q1-earnings-revenue-and-eps-beat-lifts-annual-guidance-marginally-o" rel="noreferrer noopener">Medical Devices Giant Medtronic Q1 Earnings: Revenue And EPS Beat, Lifts Annual Guidance Marginally On Sustained Growth From New Product Launches</a>.
The use of the affected product may cause serious adverse health consequences, including burns, cuts (lacerations), scarring and other tissue injuries, tooth loss, eye injury, damaged hearing (impairment or acoustic shock), or ringing in the ears (tinnitus), respiratory failure, lack of oxygen to the body (hypoxia), scarring, and death.&nbsp;
There has been one reported injury. There have been no reports of death.&nbsp;&nbsp;
This&nbsp;<a target="_blank" href="https://www.fda.gov/medical-devices/medical-device-recalls/laryngoscope-recall-medtronic-removes-certain-mcgrath-mac-video-laryngoscopes-updates-use" rel="noreferrer noopener">recall</a> involves removing certain devices from where they are used or sold.&nbsp;The FDA has identified this recall as the most serious type.
This&nbsp;recall&nbsp;also involves updating instructions for using other models of these devices.
The McGrath MAC and MAC EMS Video Laryngoscopes are used to help care providers see into the trachea during a medical procedure. The devices include a light source and a miniature camera to view the voice box (larynx) during&nbsp;laryngoscopy, a procedure that allows a doctor to examine the larynx (voice box) and nearby structures.
Wednesday, Baxter International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) <a target="_blank" href="https://www.fda.gov/medical-devices/medical-device-recalls/lung-therapy-component-recall-baxter-healthcare-corporation-recalls-certain-volara-system-single" rel="noreferrer noopener">said</a> it would recall certain Single-Patient Use Circuits and Blue Ventilator Adapter Assemblies due to reports that the handset plug within these components may disconnect from the nebulizer port on the blue ventilator adapter.
When using the Volara system in line with a ventilator and without a nebulizer connected to the blue ventilator adapter, the handset plug is required for proper operation and gas flow.
If the plug is disconnected, the ventilator may not provide enough ventilation to the patient.
The Volara System is intended for use with patients who are using a ventilator to help them breathe.
The Single Patient Use Circuit and Blue Adapter Assembly are patient circuit components that connect the Volara System to the ventilator. They are sold separately from the system.&nbsp;
Price Action: MDT stock is down 1.36% at $89.79 at last check Thursday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40736850/shell-backs-climate-technology-start-up-for-emissions-reduction-report" target="_blank" rel="noreferrer noopener">Shell Backs Climate Technology Start-up for Emissions Reduction: Report</a>.</li>
</ul>

Equities

Medtronic Recalls Some Video Laryngoscopes Due To Increased Risk For Battery Overheat, Explosion

FDA Says Baxter Healthcare Recalls Certain Volara System Single-Patient Use Circuits And Blue Ventilator Adapter Assemblies; Identified Baxter's Recall Of Certain Single Patient Use Circuits & Blue Ventilator Adapter Assemblies As Most Serious Type; Baxter Healthcare Recall Due To Disconnection Risk That May Prevent Proper Ventilation

On September&nbsp;3, 2024, the Board of Directors of the Company approved the appointment of Joel Grade, the Company&rsquo;s Executive Vice President and Chief Financial Officer, as the Company&rsquo;s Chief Accounting Officer and PAO on an interim basis, effective September&nbsp;3, 2024, while continuing to serve in his current position.

Management

Baxter And Brian Stevens Mutually Agree That He Will Resign From His Role As Senior Vice President, Chief Accounting Officer And Controller And Principal Accounting Officer - Filing

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Tencent Music Entertainment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TME#NYSE">TME</a>) shares dipped 18.18% after the company reported a <a href="https://www.benzinga.com//node/40333133" target="_blank" rel="noreferrer noopener">second-quarter revenue miss</a>. Several analysts cut <a href="https://www.benzinga.com//node/40333133" target="_blank" rel="noreferrer noopener">the price target on the stock</a>.</li>
<li>Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) stock fell 5.92% last week. RBC Capital lowered its price target on the stock <a href="https://www.benzinga.com/quote/mbly/analyst-ratings" target="_blank" rel="noreferrer noopener">from $34 to $24</a>.</li>
<li>Rivian Automotive Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) stock declined 5.37% after it reportedly halted production of the electric commercial van it makes for Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) due to a parts deficit in the latest supply chain chaos.</li>
<li>Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) stock decreased 4.87% after the company announced that Chairman and CEO Brian Niccol <a href="https://www.benzinga.com//node/40376234" target="_blank" rel="noreferrer noopener">would be leaving.</a> Several analysts revised ratings and <a href="https://www.benzinga.com//node/40367589" target="_blank" rel="noreferrer noopener">price targets on the stock</a>.</li>
<li>Lineage Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) stock lost 4.08% in the last week.</li>
<li>Sirius XM Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIRI#NASDAQ">SIRI</a>) stock fell 3.85% last week after gaining earlier in the week on reports of Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) increasing its stake in the company.</li>
<li>Hershey Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) stock lost 3.23% after Goldman Sachs issued a <a href="https://www.benzinga.com//node/40321537" target="_blank" rel="noreferrer noopener">Sell rating and</a> a price target of $185 on the stock.</li>
<li>Baxter International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) shares were down 2.80% after the company announced a <a href="https://www.benzinga.com//node/40342215">definitive agreement to divest</a> its Vantive Kidney Care segment to Carlyle Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) for $3.8 billion.</li>
<li>Broadridge Financial Solutions Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BR#NYSE">BR</a>) declined 2.76%.</li>
<li>United Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) shares decreased 2.38%.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/08/40431642/nvidia-starbucks-and-dell-are-among-top-10-large-cap-gainers-last-week-aug-11-aug-17-are-the-other" target="_blank" rel="noreferrer noopener">NVIDIA, Starbucks And Dell Are Among Top 10 Large Cap Gainers Last Week (Aug 11-Aug 17): Are The Others In Your Portfolio?</a></li>
</ul>
Photo courtesy Rivian

Movers

AMZN

LINE

MBLY

RIVN

SIRI

UTHR

Rivian, Chipotle Mexican And Sirius XM Are Among Top 10 Large Cap Losers Last Week (Aug 11-Aug 17): Are The Others In Your Portfolio?

On Tuesday, Baxter International Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) agreed to sell its Kidney Care segment, Vantive, <a href="https://www.benzinga.com/markets/equities/24/07/39663935/carlyle-eyes-4b-acquisition-of-baxters-kidney-care-unit-vantive-report" target="_blank" rel="noreferrer noopener">for $3.8 billion</a> to The Carlyle Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>)
Baxter will receive approximately $3.5 billion in cash, with net after-tax proceeds currently estimated <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40333262/baxter-announces-definitive-agreement-to-divest-its-vantive-kidney-care-segment-to-carlyle-for-3-8" rel="noreferrer noopener">at approximately $3 billion</a>.
Baxter announced its intention to create a standalone kidney care company in January 2023 as part of its broader strategic realignment designed to enhance future performance and create value for all stakeholders.
In March 2024, Baxter announced that it was in discussions to explore a <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/07/39941094/carlyles-4b-purchase-of-baxters-kidney-division-backed-by-ares-and-hps-financing" rel="noreferrer noopener">potential sale of the segment</a>.
Vantive offers products and services for peritoneal dialysis, hemodialysis, and organ support therapies, including continuous renal replacement therapy.
The business has more than 23,000 employees globally and had 2023 revenues of $4.5 billion.
The transaction is expected to close in late 2024 or early 2025.
Following the completion of the pending sale of Kidney Care, Baxter is targeting operational sales <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40191263/baxter-lifts-annual-outlook-after-strong-q2-beat-medical-devices-sales" rel="noreferrer noopener">growth of 4% to 5% annually</a>.
For 2025, the company anticipates an adjusted operating margin&nbsp;of approximately 16.5% on a continuing operations basis, which reflects an anticipated 100-basis-point negative impact due to stranded costs and the manufacturing supply agreement Baxter will enter into upon the completion of the divestiture of the Kidney Care segment.
Baxter will continue prioritizing capital allocation and expects to direct investments toward higher-growth, higher-return opportunities to drive incremental value.
To support these efforts, Baxter will focus on deleveraging and expects to achieve its investment-grade target of a debt-to-equity ratio below 3.0x by the end of 2025. This goal will be supported by using proceeds from the sale of its Kidney Care segment to repay outstanding debt, including its new bridge facility.
Price Action: BAX stock is down 6.9% at $34.37 at last check Tuesday. The stock initially gained following the announcement but has since reversed.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/08/40339633/marriott-pursues-damages-from-franchisee-for-unauthorized-hotel-use-as-migrant-shelter" target="_blank" rel="noreferrer noopener">Marriott Pursues Damages From Franchisee For Unauthorized Hotel Use As Migrant Shelter</a></li>
</ul>
Photo: Shutterstock

Baxter Seals $3.8B Deal With Carlyle For Its Kidney Care Segment

WIIM

Baxter shares are trading lower after the company announced a definitive agreement to divest its Vantive Kidney Care segment to Carlyle for $3.8 billion. The stock initially gained following the announcement but has since reversed.

The transaction is expected to close in late 2024 or early 2025, subject to receipt of customary regulatory approvals and satisfaction of other closing conditions.

Asset Sales

Baxter Intends To Use After-Tax Proceeds From Kidney Care Transaction To Reduce Its Debt, Consistent With Its Stated Capital Allocation Priorities

For 2025, the company anticipates an adjusted operating margin&nbsp;of approximately&nbsp;16.5%&nbsp;on a continuing operations basis, which reflects an anticipated 100 basis point negative impact due to stranded costs, net of anticipated transition service agreement (TSA) income, and the manufacturing supply agreement (MSA) the company will enter into upon the completion of the divestiture of the Kidney Care segment.
Baxter will continue to prioritize capital allocation and expects to direct investments toward higher-growth, higher-return opportunities to drive incremental value.&nbsp;
Additionally, the company currently expects to fully offset stranded costs and loss of TSA income in 2027 through cost containment initiatives, some of which are already underway, which will further support the company&#39;s objective of delivering annual adjusted operating margin expansion.&nbsp;
Baxter plans to provide additional details regarding the company&#39;s longer-term strategic and financial&nbsp;outlook&nbsp;at an investor conference in 2025.&nbsp;

Following Completion Of Pending Sale Of Kidney Care, Baxter Targets Operational Sales Growth Of 4% To 5% Annually

Baxter shares are trading higher after the company announced a definitive agreement to divest its Vantive Kidney Care segment to Carlyle for $3.8 billion.

Carlyle To Acquire Baxter's Kidney Care Segment, To Be Named Vantive, For $3.8B

Goldman Sachs analyst David Roman maintains Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) with a Neutral and raises the price target from $36 to $40.

Goldman Sachs Maintains Neutral on Baxter Intl, Raises Price Target to $40

JP Morgan analyst Robbie Marcus maintains Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) with a Neutral and lowers the price target from $44 to $42.

JP Morgan Maintains Neutral on Baxter Intl, Lowers Price Target to $42

In the latest quarter, 7 analysts provided ratings for Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Baxter Intl and provided 12-month price targets. The average target is $38.0, accompanied by a high estimate of $45.00 and a low estimate of $30.00. This current average has decreased by 9.95% from the previous average price target of $42.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1723050168_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Baxter Intl. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$40.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$30.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$36.00</td>
<td>-</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Hold</td>
<td>$40.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Baxter Intl. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Baxter Intl compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Baxter Intl's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Baxter Intl's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BAX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Baxter Intl analyst ratings.</a>
<h2>Unveiling the Story Behind Baxter Intl</h2>
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter offers tools to help patients with acute and chronic kidney failure, which it plans to spin off by mid-2024. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents.
<h3>Baxter Intl: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Baxter Intl's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 2.25%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Baxter Intl's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 1.03%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Baxter Intl's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.45%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Baxter Intl's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.13%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Baxter Intl's debt-to-equity ratio stands notably higher than the industry average, reaching 1.73. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings For Baxter Intl

Wells Fargo analyst Larry Biegelsen maintains Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) with a Equal-Weight and lowers the price target from $44 to $40.

Wells Fargo Maintains Equal-Weight on Baxter Intl, Lowers Price Target to $40

Biotech

FDA Says On Aug 5, Baxter Issues Voluntary Nationwide Recall Of One Lot Of Heparin Sodium 0.9% Sodium Chloride Injection; Baxter Issues Recall Of One Lot Of Heparin Sodium 0.9% Sodium Chloride Injection Due To Potential For Elevated Endotoxin Levels

The Top Five short crowded stocks in each U.S. sector

Analyst Larry Biegelsen of Wells Fargo maintained a Hold rating on Baxter International (BAX – Research Report), retaining the price target of $40....

Baxter International: Hold Rating Justified by Margin Improvements and Financial Strategy Despite Long-Term Realization

Dividend Champion, Contender, And Challenger Highlights: Week Of September 29

Medtronic Inc. is a global medical device manufacturer with leadership positions in the pacemaker, defibrillator, orthopedic, diabetes management, and other medical markets. Here are some highlights from a quantitative analysis of the stock.

Medtronic Inc. Dividend Stock Analysis - Sunday, Sept. 29

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Hold rating on Baxter International (BAX – Research Report), with a p...

Hold Rating on Baxter International Amidst Hurricane Helene's Impact on Operations

Morgan Stanley analyst Patrick Wood maintained a Sell rating on Baxter International (BAX – Research Report) today and set a price target of $30.00...

Hurricane Impact and Operational Challenges Prompt Sell Rating for Baxter International

Travis Steed, an analyst from Bank of America Securities, maintained the Hold rating on Baxter International (BAX – Research Report). The associate...

Hold Rating on Baxter International Amid Post-Hurricane Operational Challenges

The latest announcement is out from Baxter International ( ($BAX) ). Baxter International Inc. has reported that its North Cove facility in North C...

Baxter International Responds to Hurricane Impact on Facility

Baxter's largest plant knocked offline by Hurricane Helene

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Humacyte (HUMA – Research Report) and Baxter Inter...

Analysts Conflicted on These Healthcare Names: Humacyte (HUMA) and Baxter International (BAX)

APLE

ASIX

AVNW

BEPC

BIRD

BMBL

BPOP

CABO

CADE

CBRL

CERT

CFFI

CHCO

CHRW

CMCSA

CMTL

CSCO

CTBI

CUBE

ECVT

ERIE

EVTC

FFIN

FISI

FMAO

FULT

FUNC

GAIN

HBNC

HLNE

HUMA

HWBK

IART

INDB

INGR

INST

LRCX

MBIN

MNTK

MORN

NAPA

NEWT

NTST

NXDT

PDCO

REXR

RGLD

SCVL

SFBS

SFNC

SPTN

SWBI

SYBT

THFF

TROW

UBSI

ULCC

UMBF

UTMD

VICI

VTLE

WASH

WSBC

Press Releases

Baxter publishes annual corporate responsibility report, highlighting continued focus on creating lasting impact

Baxter Declares Quarterly Dividend

Baxter to Host Second-Quarter 2024 Financial Results Conference Call for Investors

Baxter Reports Second-Quarter 2024 Results

Baxter Announces Definitive Agreement to Divest Its Vantive Kidney Care Segment to Carlyle for $3.8 Billion

Baxter to Present at 2024 Wells Fargo Healthcare Conference

Spectral Medical Provides August Tigris Trial Update

Baxter Appoints Jeffrey A. Craig to Its Board

Baxter Launches Next Generation of The Vest System for Airway Clearance

Baxter Provides Update on North Cove, N.C., Facility and Hurricane Helene Relief Plans for Community

Comments

Baxter Intl

Intérêt court

Baxter Intl (NYSE:BAX) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL